Regulation of bladder muscarinic receptor subtypes by experimental pathologies.
1 The M3 muscarinic receptor subtype is widely accepted as the receptor on smooth muscle cells that mediates cholinergic contraction of the normal urinary bladder and other smooth muscle tissues, however, we have found that the M2 receptor participates in contraction under certain abnormal conditions. The aim of this study was to determine the effects of various experimental pathologies on the muscarinic receptor subtype mediating urinary bladder contraction. 2 Experimental pathologies resulting in bladder hypertrophy (denervation and outlet obstruction) result in an up-regulation of bladder M2 receptors and a change in the receptor subtype mediating contraction from M3 towards M2. Preventing the denervation-induced bladder hypertrophy by urinary diversion prevents this shift in contractile phenotype indicating that hypertrophy is responsible as opposed to denervation per se. 3 The hypertrophy-induced increase in M2 receptor density and contractile response is accompanied by an increase in the tissue concentrations of mRNA coding for the M2 receptor subtype, however, M3 receptor protein density does not correlate with changes in M3 receptor tissue mRNA concentrations across different experimental pathologies. 4 This shift in contractile phenotype from M3 towards M2 subtype is also observed in aged male Sprague-Dawley rats but not females or either sex of the Fisher344 strain of rats. 5 Four repeated, sequential agonist concentration response curves also cause this shift in contractile phenotype in normal rat bladder strips in vitro, as evidenced by a decrease in the affinity of the M3 selective antagonist p-fluoro-hexahydro-sila-diphenidol (p-F-HHSiD). 6 A similar decrease in the contractile affinity of M3 selective antagonists (darifenacin and p-F-HHSiD) is also observed in bladder specimens from patients with neurogenic bladder as well as certain organ transplant donors. 7 It is concluded that although the M3 receptor subtype predominantly mediates contraction under normal circumstances, the M2 receptor subtype can take over a contractile role when the M3 subtype becomes inactivated by, for example, repeated agonist exposures or bladder hypertrophy. This finding has substantial implications for the clinical treatment of abnormal bladder contractions.
Ruggieri
M R
MR
Department of Urology, Temple University, Philadelphia, PA, USA.
Braverman
A S
AS
D000367:Age Factors; D000818:Animals; D001572:Benzofurans / Q000494:pharmacology; D002217:Carbachol / Q000494:pharmacology; D003714:Denervation; D004195:Disease Models, Animal; D004558:Electric Stimulation; D005260:Female; D005786:Gene Expression Regulation; D006801:Humans; D006984:Hypertrophy; D008297:Male; D018721:Muscarinic Agonists / Q000494:pharmacology; D018727:Muscarinic Antagonists / Q000494:pharmacology; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects / Q000294:innervation / Q000378:metabolism / Q000473:pathology; D010880:Piperidines / Q000494:pharmacology; D011759:Pyrrolidines / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D011916:Rats, Inbred F344; D017207:Rats, Sprague-Dawley; D043585:Receptor, Muscarinic M2 / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D043587:Receptor, Muscarinic M3 / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D001743:Urinary Bladder / Q000187:drug effects / Q000294:innervation / Q000378:metabolism* / Q000473:pathology; D001748:Urinary Bladder Neck Obstruction / Q000378:metabolism* / Q000473:pathology; D001750:Urinary Bladder, Neurogenic / Q000378:metabolism* / Q000473:pathology
D001572:Benzofurans; D018721:Muscarinic Agonists; D018727:Muscarinic Antagonists; D010880:Piperidines; D011759:Pyrrolidines; D012333:RNA, Messenger; D043585:Receptor, Muscarinic M2; D043587:Receptor, Muscarinic M3; C058297:4-fluorohexahydrosiladifenidol; D002217:Carbachol; C101207:darifenacin